3iu3 › Citations

Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab.

Du J, Yang H, Zhang D, Wang J, Guo H, Peng B, Guo Y, Ding J
J Immunol 184 1361-8 (2010)
Cited: 28 times
EuropePMC logo PMID: 20032294

Abstract

IL-2 signaling plays a central role in the initiation and activation of immune responses. Correspondingly, blockage of this pathway leads to inhibition of the immune system and would provide some therapeutic benefits. Basiliximab (Simulect), a therapeutic mAb drug with specificity against IL-2R alpha of T cells, was approved by U.S. Food and Drug Administration in 1998. It has been proven to be effective in the suppression of the IL-2 pathway and hence has been widely used to prevent allograft rejection in organ transplantation, especially in kidney transplants. In this study, we report the crystal structure of the basiliximab Fab in complex with the ectodomain of IL-2R alpha at 2.9 A resolution. In the complex structure, the Fab interacts with IL-2R alpha with extensive hydrophobic and hydrophilic interactions, accounting for a high binding affinity of 0.14 nM. The Ag binding site of basiliximab consists of all six CDR loops that form a large binding interface with a central shallow hydrophobic groove surrounded by four hydrophilic patches. The discontinuous epitope is composed of several segments from the D1 domain and a minor segment from the D2 domain that overlap with most of the regions responsible for the interactions with IL-2. Thus, basiliximab binding can completely block the interactions of IL-2 with IL-2R alpha and hence inhibit the activation of the IL-2 signal pathway. The structural results also provide important implications for the development of improved and new IL-2R alpha-targeted mAb drugs.

Articles - 3iu3 mentioned but not cited (10)

  1. OptMAVEn--a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes. Li T, Pantazes RJ, Maranas CD. PLoS One 9 e105954 (2014)
  2. Antibody humanization by structure-based computational protein design. Choi Y, Hua C, Sentman CL, Ackerman ME, Bailey-Kellogg C. MAbs 7 1045-1057 (2015)
  3. MimoPro: a more efficient Web-based tool for epitope prediction using phage display libraries. Chen WH, Sun PP, Lu Y, Guo WW, Huang YX, Ma ZQ. BMC Bioinformatics 12 199 (2011)
  4. Epitope prediction based on random peptide library screening: benchmark dataset and prediction tools evaluation. Sun P, Chen W, Huang Y, Wang H, Ma Z, Lv Y. Molecules 16 4971-4993 (2011)
  5. A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers. Dehbashi M, Hojati Z, Motovali-Bashi M, Ganjalikhany MR, Cho WC, Shimosaka A, Navabi P, Ganjalikhani-Hakemi M. Front Oncol 11 649710 (2021)
  6. A complete, multi-level conformational clustering of antibody complementarity-determining regions. Nikoloudis D, Pitts JE, Saldanha JW. PeerJ 2 e456 (2014)
  7. PepMapper: a collaborative web tool for mapping epitopes from affinity-selected peptides. Chen W, Guo WW, Huang Y, Ma Z. PLoS One 7 e37869 (2012)
  8. Conformational B-cell epitope prediction method based on antigen preprocessing and mimotopes analysis. Sun P, Ju H, Zhang B, Gu Y, Liu B, Huang Y, Zhang H, Li Y. Biomed Res Int 2015 257030 (2015)
  9. Antibody-guided design and identification of CD25-binding small antibody mimetics using mammalian cell surface display. See K, Kadonosono T, Miyamoto K, Tsubaki T, Ota Y, Katsumi M, Ryo S, Aida K, Minegishi M, Isozaki T, Kuchimaru T, Kizaka-Kondoh S. Sci Rep 11 22098 (2021)
  10. Structural and functional analyses of Burkholderia pseudomallei BPSL1038 reveal a Cas-2/VapD nuclease sub-family. Shaibullah S, Shuhaimi N, Ker DS, Mohd-Sharif N, Ho KL, Teh AH, Waterman J, Tang TH, Wong RR, Nathan S, Mohamed R, Ng MJ, Fung SY, Jonet MA, Firdaus-Raih M, Ng CL. Commun Biol 6 920 (2023)


Reviews citing this publication (4)

  1. Current approaches to fine mapping of antigen-antibody interactions. Abbott WM, Damschroder MM, Lowe DC. Immunology 142 526-535 (2014)
  2. Multispecific drugs herald a new era of biopharmaceutical innovation. Deshaies RJ. Nature 580 329-338 (2020)
  3. Impact of Immune-Modulatory Drugs on Regulatory T Cell. Furukawa A, Wisel SA, Tang Q. Transplantation 100 2288-2300 (2016)
  4. Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected? Zhang Z, Hu W, Li L, Ding H, Li H. J Clin Lab Anal 32 (2018)

Articles citing this publication (14)

  1. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Nat Cancer 1 1153-1166 (2020)
  2. IL-10-Modulated Human Dendritic Cells for Clinical Use: Identification of a Stable and Migratory Subset with Improved Tolerogenic Activity. Kryczanowsky F, Raker V, Graulich E, Domogalla MP, Steinbrink K. J Immunol 197 3607-3617 (2016)
  3. CD25 appears non essential for human peripheral T(reg) maintenance in vivo. de Goër de Herve MG, Gonzales E, Hendel-Chavez H, Décline JL, Mourier O, Abbed K, Jacquemin E, Taoufik Y. PLoS One 5 e11784 (2010)
  4. Structural basis of immunosuppression by the therapeutic antibody daclizumab. Yang H, Wang J, Du J, Zhong C, Zhang D, Guo H, Guo Y, Ding J. Cell Res 20 1361-1371 (2010)
  5. IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design. Stoyle CL, Stephens PE, Humphreys DP, Heywood S, Cain K, Bulleid NJ. Biochem J 474 3179-3188 (2017)
  6. Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation. López-Abente J, Martínez-Bonet M, Bernaldo-de-Quirós E, Camino M, Gil N, Panadero E, Gil-Jaurena JM, Clemente M, Urschel S, West L, Pion M, Pion M, Correa-Rocha R. Sci Rep 11 827 (2021)
  7. Letter Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy. Heidt S, Shankar S, Muthusamy AS, San Segundo D, Wood KJ. Transplantation 91 e59-61 (2011)
  8. p-TSA-promoted syntheses of 5H-benzo[h] thiazolo[2,3-b]quinazoline and indeno[1,2-d] thiazolo[3,2-a]pyrimidine analogs: molecular modeling and in vitro antitumor activity against hepatocellular carcinoma. Keshari AK, Singh AK, Raj V, Rai A, Trivedi P, Ghosh B, Kumar U, Rawat A, Kumar D, Saha S. Drug Des Devel Ther 11 1623-1642 (2017)
  9. AKT family and miRNAs expression in IL-2 induced CD4(+)T cells. Ranji N, Sadeghizadeh M, Karimipoor M, Shokrgozar MA, Ebrahimzadeh-Vesal R. Iran J Basic Med Sci 17 886-894 (2014)
  10. Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. Price-Troska T, Yang ZZ, Diller D, Bayden A, Jarosinski M, Audie J, Ansell SM. Invest New Drugs 37 9-16 (2019)
  11. Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): An in silico and in vitro study. Navabi P, Ganjalikhany MR, Jafari S, Dehbashi M, Ganjalikhani-Hakemi M. Iran J Basic Med Sci 24 360-368 (2021)
  12. Indole-fused benzooxazepines: a new structural class of anticancer agents. Singh AK, Raj V, Rai A, Keshari AK, Saha S. Future Sci OA 3 FSO168 (2017)
  13. Establishing a novel and sensitive assay for bioactivity determination of anti-CD25 antibodies. Duan M, Yu C, Yang Y, Fu Z, Liu C, Du J, Li M, Guo S, Yu X, Xu G, Mei Y, Wang L. Heliyon 9 e17401 (2023)
  14. Case Reports Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report. Zarrabi M, Hamilton C, French SW, Federman N, Nowicki TS. Front Immunol 14 1156746 (2023)


Quick links